Is there a Future for <i>CYP1A2</i> Pharmacogenetics in the Optimal Dosing of Clozapine?
Can‐Jun Ruan, José de León
Abstract
In 1989, clozapine (CLO) was marketed in the USA with limited pharmacokinetic studies. In 1994, Bertilsson et al. described CYP1A2 as explaining 70% of CLO metabolism [1]. While in vitro studies su...
Topics & Concepts
DosingMedicinePharmacogeneticsPsychiatryClozapineMEDLINEConfoundingPharmacologySchizophrenia (object-oriented programming)PsychologyFamily medicineInternal medicineChemistryGenotypeBiochemistryGenePharmacogenetics and Drug MetabolismSchizophrenia research and treatmentPharmaceutical studies and practices